April 24, 2008 - Cure Lab publishes results on a new technology for boosting immune response to viral and potentially cancer antigens.

This research was published in the journal Vaccine, and covered by scientific news media sources from around the world

January 31, 2008 - Cure Lab, Inc. is awarded Phase I of an SBIR NIH grant to develop a patent-pending technology on vaccine codon optimization.

January 16, 2008 - Cure Lab, Inc. publishes results on potential negative contribution of M2 protein of influenza virus when used as a part of a recombinant vaccine regimen.

This publication also discloses some of the patent pending methods by which the negative contribution of M2 is eliminated while still preserving its protective potency. This publication has received significant media coverage:

December 1, 2007 - Cure Lab, Inc. has submitted a provisional patent on method and composition of an anti-influenza vaccine. Cure Lab has demonstrated that M2 protein of influenza virus may contribute both positively and negatively when used a part of a vaccination regimen. The subject matter of the patent allows incorporation of M2 into an anti-influenza recombinant vaccine free of the negative contribution.

November 15, 2007 - Cure Lab, Inc. submits a provisional patent application on a new composite antigen consisting of a proprietary combination of conserved influenza genes. This antigen has demonstrated enhanced protection properties when tested in vivo.

October 26, 2007 - Cure Lab, Inc. submits a patent application on the technology for enhancing the immunogenicity of a recombinant vaccine via utilization of a combination of alternative forms of the gene coding for an antigen protein.

September 25, 2007 - Cure Lab Inc. submits a provisional patent application on technology that allows for the increase in efficiency of vaccination with recombinant vaccines.

September 21, 2007 - Cure Lab Inc. submits a provisional patent application for a novel molecular adjuvant.

August 15, 2007 - New target for anti-flu drug development

June 22, 2007 - Cure Lab, Inc. has submitted a provisional patent on an alternative application of a previously known and commercially available drug.

May 9, 2007 - Cure Lab publishes results on immunization with its patent pending vaccine prototype based on a combination of influenza A NP, M1 and NS1-expressing plasmids demonstrating protection of mice against experimental infection with human and avian influenza viruses, as well as protection of chicken against avian influenza infection.

October 18-20, 2006 - Cure Lab, Inc. is represented at the INFLUENZA VACCINES FOR THE WORLD - IVW 2006 CONFERENCE, held on 18-20 October 2006 in Vienna, Austria. Cure Lab CEO, Dr. Alex Shneider, presented a talk entitled "Anti-influenza vaccination with a combination of NP, M1 and NS1 proteins.

September 12, 2006 - Cure Lab, Inc. submits a proposal entitled "DNA vaccine against epidemic and potentially pandemic influenza strains"

June 16, 2006 - Cure Lab, Inc, announced today that it has reached an agreement to engage DLA Piper Rudnick Gray Cary (DLA Piper).

June 6, 2006 - Cure Lab initiates a product development program aimed at 1.) modification of influenza virus M2 protein, and 2.) utilization of modified M2 as a vaccine component.

April 27, 2006 - Cure Lab submits a utility patent application for product prototype CLVax 1.0

March 30, 2006 - Cure Lab establishes a research consortium with MIT on joint development of a novel family of vaccine adjuvants.

January 26, 2006 - Cure Lab, Inc. hosts a panel discussion on viro-therapy in Cambridge, Massachusetts.

January 1, 2006 - Cure Lab, Inc. moves to new location.

November 15, 2005 - Cure Lab publishes results on immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses.

September 13, 2005 - Cure Lab tests the protective effect of its product prototype CLVax 1.0 on chicken challenged with H5N3 avian flu virus. CLVax 1.0 demonstrates a statistically significant level of protection against lethal doses of the virus.

August 2, 2005 - Cure Lab publishes results on combined prime-boost vaccination against tick-borne encephalitis (TBE) using a recombinant vaccinia virus and a bacterial plasmid both expressing TBE virus non-structural NS1 protein.

July 1, 2005 - Cure Lab is awarded an NIH Biodefense SBIR for development of broad range anti-influenza vaccine.

June 13, 2005 - Cure Lab tests the protective effect of its product prototype CLVax 1.0 on mice challenged with H5N2 mouse adapted avian flu virus. CLVax 1.0 demonstrates a statistically significant level of protection against lethal doses of the virus.

March 15, 2005 - Cure Lab tests the protective effect of its product prototype CLVax 1.0 on mice challenged with H3N2 mouse adapted human flu virus. CLVax 1.0 demonstrates a complete protection against lethal doses of the virus.

August 1, 2005 - Cure Lab submits a provisional patent application for product prototype CLVax 1.0

July 18-23, 2004 - Cure Lab presents at the 12th International Congress of Immunology and 4th International Conference of FOCIS, Montreal, Canada.

June 11, 2004 - Cure Lab submits a patent application on vaccine compositions and methods.

January 31, 2004 - Cure Lab raises a seed round of private investment funding.

December 19, 2003 - Cure Lab submits a patent application on vaccine compositions and methods.

December 15, 2003 - Cure Lab publishes results on vaccinia virus recombinant expressing gene of tick-borne encephalitis virus non-structural NS1 protein elicits protective activity in mice.